Spinout

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, June 29, 2023
Empyrean, Psilocybin, BioImpacts, Toronto Stock Exchange, PD, Glenmark Pharmaceuticals, D.O, Reunion, Pharmacovigilance, Biotechnology, Scientific Research and Experimental Development Tax Credit Program, Calendar, Woman, Arrangement, Bristol Myers Squibb, FAPA, Trial of the century, ASCP, Eli Lilly, Spinout, Annual general meeting, Drug discovery, TSX, Chief Medical Officer of Hungary, Johnson & Johnson, Research, Society, MPM, Scientific method, Pharmaceutical industry, Cryptocurrency

TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the "Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Shareholders will be entitled to receive US$1.12 in cash for each share held immediately prior to the effective time of the take-private transaction.
  • The transaction is currently contemplated to close in the third calendar quarter of 2023, subject to satisfaction of certain closing conditions.
  • On April 3, 2023, Reunion announced that it appointed seasoned pharmaceutical executive, Fred Grossman, D.O., FAPA, to its Board of Directors.
  • Drug Effect Questionnaire and Mystical Effect Questionnaire scores observed at these dose levels indicate the potential for therapeutic effect.

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 14, 2023
Bank statement, GSK, Woman, Mother, TSX, Data analysis, Investment, PPD, IAS, ID, Safety, Patient, Depression, Webcast, International Financial Reporting Standards, Reunion, Congress, Takeda, Psilocybin, Psychopharmacology, International, FDA, Consciousness, Research, Wellness, Spinout, AstraZeneca, Drug discovery, Toronto Stock Exchange, Selective serotonin reuptake inhibitor, Management, Pharmaceutical industry, Audit, Cryptocurrency, Pfizer, Merck

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and reported fiscal results for the third quarter ended December 31, 2022.

Key Points: 
  • In January 2023, Reunion completed its Phase 1 interim data analysis, which showed that RE104 was safe and well tolerated, with no serious or severe adverse events.
  • Exploring further doses with the two additional planned cohorts will provide Reunion with valuable data to inform selection of a recommended Phase 2 dose.
  • Reunion will conduct a conference call and webcast to discuss its results on February 14, 2023, at 8:30 a.m.
  • A live webcast of the conference call can be accessed via the “Events and Presentations” section of the Reunion investor relations website here .

Pan American Energy Corp. Intends to “Spin-out” Utah Property

Retrieved on: 
Tuesday, January 3, 2023
Lithium, Spinning Out, Spinout, Property, FSE, CSE, OTC, Arrangement, Canada Business Corporations Act, Security (finance), Pan-American

VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG) (OTC PINK: PAANF) (FSE: SS6) (the “Company” or “Pan American”) is pleased to announce that, following careful review, the Company intends to “spin-out” its Green Energy Lithium Project, located in Cane Creek Anticline, Grand County, Utah, USA (the “Property”), into a wholly-owned subsidiary (“Subco”).

Key Points: 
  • VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG) (OTC PINK: PAANF) (FSE: SS6) (the “Company” or “Pan American”) is pleased to announce that, following careful review, the Company intends to “spin-out” its Green Energy Lithium Project, located in Cane Creek Anticline, Grand County, Utah, USA (the “Property”), into a wholly-owned subsidiary (“Subco”).
  • There will be no change in shareholders’ holdings in Pan American as a result of the Arrangement.
  • Pan American believes that its current share price does not fully recognize the value of the Property, and that by completing the proposed Arrangement, the shareholders of the Company will benefit from unlocking the value of the Property.
  • Jason Latkowcer, Chief Executive Officer of Pan American, commented, “The Spin Out allows us to more acutely focus our human capital and other resources.

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

Retrieved on: 
Monday, November 14, 2022
Trial of the century, Toronto Stock Exchange, Patent, International, Safety, IAS, US FDA, Webcast, Investment, Medical Affairs Bureau, Spinout, Research, Depression, EDGAR, Drug discovery, PPD, International Financial Reporting Standards, NCE, General counsel, US, TSX, Pharmacokinetics, IND, Wellness, SEDAR, Calendar, Risk, Mental health, Family, Patient, Pharmaceutical industry, Management, Audit

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported its business update and fiscal second quarter ended September 30, 2022 results.

Key Points: 
  • TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported its business update and fiscal second quarter ended September 30, 2022 results.
  • We are well positioned to round out the year in preparation for what promises to be an exciting 2023.
  • The study aims to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of RE104 over a range of dosage levels.
  • Per the Phase 1 protocol, up to two additional dosing cohorts may be evaluated based on pharmacokinetics, pharmacodynamics and safety.

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Retrieved on: 
Thursday, June 30, 2022
Patient, Research, TSX, GLOBE, Marketing, Growth, Company, Psilocybin, Mission statement, Spinout, Family, Drug development, Patent, Contract research organization, Efficiency, Depreciation, TSX Venture Exchange, Nasdaq, Travel, Exercise, Association, Pharmacokinetics, Wellness, Field trip, Concurrency, Intention, International Financial Reporting Standards, Acquisition, IAS, CEO, Ketamine, Lists of diseases, Substance abuse, DC, Toronto Stock Exchange, CRO, IFRS, NASDAQ, Board, Mental health, Drug discovery, Method, Anxiety, International, R, Depression, 1836 U.S. Patent Office fire, District, Reunion, PAT, Safety, Home Power, Pharmaceutical industry, Online gambling, Security (finance), Management, BC, Arrangement

In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.

Key Points: 
  • In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.
  • TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and provided a business update.
  • Post quarter end, Field Trip announced the completion of its previously announced strategic review and the intention to complete a reorganization that will separate the Field Trip Discovery and Field Trip Health Divisions into two independent public companies (the Spinout Transaction).
  • Throughout the fiscal fourth quarter, the Company continued to implement operational improvements to reduce costs and increase throughput at its Field Trip Health Centers.

Palliare Completes $8m Series A Funding Round

Retrieved on: 
Monday, June 28, 2021
Professional services, Medical devices, Health, Surgery, Finance, Biotechnology, Supply chain management, Spinout, Jennifer McMahon, MDT, Subscription, New York Stock Exchange, Medtronic, Finance, Economy, the EVA15 Insufflator, Palliare, THE EVA15 INSUFFLATOR, PALLIARE

Palliare, an emerging company with the vision to create a safer operating room, today announced the closing of an oversubscribed $8 million Series A funding round.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, today announced the closing of an oversubscribed $8 million Series A funding round.
  • With the close of the Series A round, Jennifer McMahon, Principal at Seroba, will join the board.
  • Jennifer commented, We are delighted to back the experienced Palliare team who have identified the clinical need for a user-friendly continuous pressure insufflator.
  • Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Larose Announces Approval and Closing of Plan of Arrangement

Retrieved on: 
Friday, April 2, 2021
Articles, Corporate law, Board of directors, Business law, Committees, Spinout, Larose

Vancouver, British Columbia--(Newsfile Corp. - April 1, 2021) - Larose Ventures Ltd. (the "Company" or "Larose") and 1290439 B.C.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 1, 2021) - Larose Ventures Ltd. (the "Company" or "Larose") and 1290439 B.C.
  • The Arrangement was approved by the unanimous written consent of the shareholders of the Company.
  • The Company obtained the final order approving the Arrangement from the Supreme Court of British Columbia on March 26, 2021 and the Arrangement closed and became effective on April 1, 2021.
  • On Behalf of the Board of Directors of Larose and each of the Spinout Entities.

Palliare Announces New Board Appointment

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Surgery, Medical devices, Hospitals, Health, Spinout, MDT, Medtronic, New York Stock Exchange, Insufflation, Medicine, Health sciences, Health, the EVA15 Insufflator, Palliare

Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.
  • Commenting on the new Board appointment, Scott Flora, Chairman, said, We are pleased to welcome Samantha Bonano to the Board.
  • With the pending US commercial release of our EVA15 insufflation and smoke evacuation system, her previous experience in developing a world leader in smoke evacuation will bring a valued mindset to the Board.
  • Palliare Ltd was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Palliare Announces Organizational Changes

Retrieved on: 
Monday, December 7, 2020
Biotechnology, FDA, Surgery, Medical devices, Health, Medtronic, MDT, Spinout, the EVA15 Insufflator, Palliare, PORSAV

Palliare, an emerging company with the vision to create a safer operating room, has appointed John ODea as Group CEO.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, has appointed John ODea as Group CEO.
  • Caroline ODea will continue in her current role as Managing Director of the Irish operation of Palliare.
  • Palliare Ltd was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.
  • PORSAV (Protecting OR Staff from Aerosolized Virus) is an EU-funded project that emanated out of collaborative work between Palliare and Professor Ronan Cahill of University College Dublin.

The Alpha Group Announces Rebrand to Project Text

Retrieved on: 
Tuesday, October 22, 2019
Songs, Blog software, Subtext, World Wide Web, Spinout

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- The Alpha Group , an in-house tech and media incubator within Advance Local, today announces the rebrand of the companys fourth product spinout Project Text.

Key Points: 
  • NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- The Alpha Group , an in-house tech and media incubator within Advance Local, today announces the rebrand of the companys fourth product spinout Project Text.
  • Project Text will now be known as Subtext .
  • Since Project Text was released earlier this year, weve seen really impressive growth across the platform.
  • Subtext is the fourth product spinout from Alpha Group, a successful incubator for new technology and media properties inside Advance Local.